Biomedical Engineering Reference
In-Depth Information
References
1. Mitchell JP, Newman SP, Chan H-K (2007) In vitro and in vivo aspects of cascade impactor
tests and inhaler performance: a review. AAPS PharmSciTech 8(4): article 24 at:
http://www.
aapspharmscitech.org/view.asp?art=pt0804110
. Accessed 23 Jan 2012
2. Newman SP, Chan H-K (2008) In vitro/in vivo comparisons in pulmonary drug delivery.
J Aerosol Med 21(1):1-8
3. Gonda I (1990) Aerosols for delivery of therapeutic and diagnostic agents to the respiratory
tract. Crit Rev Ther Drug Carrier Syst 7:273-313
4. Patton JS, Bukar JG, Eldon MA (2004) Clinical pharmacokinetics and pharmacodynamics of
inhaled insulin. Clin Pharmacokinet 43(12):781-801
5. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ (2003) Effects of
bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol
95(5):2106-2112
6. Usmani OS, Biddiscombe MF, Barnes PJ (2005) Regional lung deposition and bronchodilator
response as a Function of β
2
-agonist particle size. Am J Respir Crit Care Med 172(12):
1497-1504
7. Dunbar C, Mitchell JP (2005) Analysis of cascade impactor mass distributions. J Aerosol Med
18(4):439-451
8. Vincent JH (1995) The inhalation of aerosols. In: Vincent JH (ed) Aerosol science for indus-
trial hygienists. Pergamon Press, Oxford, pp 136-155
9. Dolovich MB, Rhem R (1998) Impact of oropharyngeal deposition on inhaled dose. J Aerosol
Med 11(S1):S112-S115
10. Borgström L, Olsson B, Thorsson L (2006) Degree of throat deposition can explain the vari-
ability in lung deposition of inhaled drugs. J Aerosol Med 19(4):473-483
11. Cheng YS, Zhou Y, Chen BT (1999) Particle deposition in a cast of human oral airways.
Aerosol Sci Technol 31(4):286-300
12. Swift DL (1992) Apparatus and method for measuring regional distribution of therapeutic
aerosols and comparing delivery systems. J Aerosol Sci 23(S1):S495-S498
13. Berg E (1995) In vitro properties of pressurized metered dose inhalers with and without spacer
devices. J Aerosol Med 8(S3):S3-S11
14. Velasquez DJ, Gabrio B (1998) Metered dose inhaler aerosol deposition in a model of the
human respiratory system and a comparison with clinical deposition studies. J Aerosol Med
11(S1):S23-S28
15. Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House KW, Ortega HG (2009)
Pharmacokinetic, pharmacodynamic, effi cacy, and safety data from two randomized, double-
blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers
delivering a combination of salmeterol 50 µg and fl uticasone propionate 250 µg: implications
for establishing bioequivalence of inhaled products. Clin Thera 31(2):370-385
16. Grgic B, Finlay WH, Burnell PKP, Heenan AF (2004) In vitro intersubject and intrasubject
deposition measurements in realistic mouth-throat geometries. J Aerosol Sci 35(8):1025-1040
17. Finlay WH (2012) New validated extrathoracic and pulmonary deposition models for infants
and children. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (eds) Respiratory
drug delivery-2012. Davis HealthCare International Publishing, River Grove, IL, pp 325-336
18. Golshahi L, Noga ML, Thompson RB, Finlay WH (2011) In vitro deposition measurement of
inhaled micrometer-sized particles in nasal airways of children and adolescents during nose
breathing. J Aerosol Sci 42(7):474-488
19. Golshahi L, Noga ML, Finlay WH (2012) Deposition of inhaled micrometer-sized particles in
oropharyngeal airway replicas of children at constant fl ow rates. J Aerosol Sci 49(1):21-31
20. Rennard SI (2005) Anticholinergics in combination bronchodilator therapy in COPD. In:
Spector SL (ed) Anticholinergic agents in the lower and upper airways. Dekker, New York,
NY, pp 97-111
Search WWH ::
Custom Search